The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Hypertrophic cardiomyopathy is a heart condition where the heart muscle becomes abnormally thick. This makes it harder for the heart to work correctly. Obstructive hypertrophic cardiomyopathy (oHCM) ...

Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. We conducted a phase 3, ...

Aficamten offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed aficamten's efficacy in improving exercise ...

The hypertrophic cardiomyopathies include several diseases with different etiologies, all of which are characterized by abnormal thickening of the myocardium, most commonly in the interventricular ...

The trial met its primary endpoint demonstrating the superiority of aficamten in improving peak exercise capacity compared with metoprolol. Topline results were announced from a phase 3 study ...

Treatment with aficamten improved exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy when compared with placebo. Treatment with aficamten improved exercise capacity ...

Experts released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). The guideline reiterates the importance of collaborative ...

Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to meet its dual primary endpoints. In ...

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), ...

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...